FDA issues new guidance on drug approval timelines by 2026

Anticipating a leadership change, the FDA will publish updated guidelines to streamline drug approval processes, reducing average review times by at least 10%. This aligns with industry demands for faster commercialization.

Implied probability (Yes)

60%